IMNN-001 with Chemotherapy for Advanced Ovarian Cancer

Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer

Recruiting Phase 3 Interventional Study
Epithelial Ovarian Cancer Ovarian Cancer Fallopian Tube Cancer Primary Peritoneal Carcinoma
No Placebo Group Every participant receives an active treatment — no one gets a placebo. Pivotal Trial This treatment is in the last trial phase before FDA approval. Prior Safety Data This treatment has already been tested in at least one earlier human trial.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 and older
Sex
Female
Trial phase
Phase 3
Study type
Interventional
Purpose
Treatment
Participants needed
500 (estimated)
Sponsor
Imunon · Industry
Who this trial is looking for

This trial is looking for women aged 18 and older who have been diagnosed with advanced ovarian, fallopian tube, or peritoneal cancer. Participants will receive a new treatment called IMNN-001 along with standard chemotherapy to see how effective and safe it is.

Are You a Good Fit for This Trial?
Rules you out Active autoimmune diseaseCNS disease

You may be able to join if

  • I am a female aged 18 or older.
  • I have been diagnosed with advanced ovarian or related cancer.
  • I am eligible to receive neoadjuvant chemotherapy.
  • I can provide a tumor tissue sample for testing.
  • I have a negative pregnancy test and use effective contraception.
  • I have adequate blood and organ function.
  • I have a good performance status (ECOG score of 0, 1, or 2).
  • I am free of active infections and serious uncontrolled medical issues.

You may not be able to join if

  • I have previously received treatment with IMNN-001.
  • I am currently taking corticosteroids or other immunosuppressive therapy.
  • I have a type of ovarian cancer that is not eligible for this trial.
  • I have had certain medical issues or treatments in the last few years.
  • I am pregnant or breastfeeding.
  • I have any known active hepatitis or HIV.
  • I have had recent radiation therapy or chemotherapy for specific cancers.
  • I have a history of severe neurological issues.

Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.

Think this trial could be right for you?

Answer three quick questions written from this study's own rules to see if you may qualify. No account needed to find out.

Check Your Eligibility
About This Trial

This is a randomized, adaptive, open label, multicenter trial to evaluate the safety and efficacy of intraperitoneal (IP) IMNN-001 plus chemotherapy compared to chemotherapy alone.

Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: 1. Participants must be female, ≥18 years of age, able to understand the study procedures, and agree to participate in the study by providing written informed consent. 2. Participants with a histologically confirmed diagnosis of high-grade non-mucinous epithelial ovarian (serous…
Contacts

Douglas Faller, M.D.

+1 609 896 9100

dfaller@imunon.com

CONTACT

Lauren Musso

+1 609 896 9100

lmusso@imunon.com

CONTACT